The European CDMO sector stands at a pivotal moment defined by disruption from inflation, geopolitical changes, and health crises. These challenges present opportunities for growth through antifragility, a concept advocating that organizations can thrive on adversity. By stepping beyond the subcontractor role, CDMOs can secure their importance in the biopharma ecosystem. They must exploit their strengths in high-value production and regulatory credibility to thrive amidst disruptions like Brexit and the Biosecure Act, framing these challenges as pathways to a resilient future.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.